Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 08  •  04:00PM ET
3.64
Dollar change
+0.04
Percentage change
1.11
%
Index
RUT
P/E
1.91
EPS (ttm)
1.90
Insider Own
8.18%
Shs Outstand
59.33M
Perf Week
-60.56%
Market Cap
215.95M
Forward P/E
1.81
EPS next Y
2.01
Insider Trans
0.00%
Shs Float
54.48M
Perf Month
-58.96%
Enterprise Value
1.40B
PEG
-
EPS next Q
0.41
Inst Own
92.41%
Perf Quarter
-66.50%
Income
111.90M
P/S
0.21
EPS this Y
-36.10%
Inst Trans
3.33%
Perf Half Y
-73.74%
Sales
1.04B
P/B
-
EPS next Y
6.49%
ROA
10.41%
Perf YTD
-69.36%
Book/sh
-10.55
P/C
1.12
EPS next 5Y
-13.11%
ROE
-
52W High
15.55 -76.59%
Perf Year
-72.63%
Cash/sh
3.26
P/FCF
1.05
EPS past 3/5Y
-25.52% -
ROIC
15.38%
52W Low
3.45 5.51%
Perf 3Y
-87.59%
EV/EBITDA
3.84
Sales past 3/5Y
-1.47% -0.10%
Gross Margin
62.52%
Volatility
13.37% 5.94%
Perf 5Y
-
EV/Sales
1.34
EPS Y/Y TTM
109.76%
Oper. Margin
29.78%
ATR (14)
0.64
Perf 10Y
-
Quick Ratio
1.68
Sales Y/Y TTM
-3.43%
Profit Margin
10.73%
RSI (14)
14.78
Current Ratio
2.46
EPS Q/Q
-117.21%
SMA20
-55.40%
Beta
0.97
Debt/Eq
-
Sales Q/Q
-14.36%
SMA50
-58.16%
Rel Volume
4.97
Prev Close
3.60
Employees
1850
LT Debt/Eq
-
SMA200
-69.01%
Avg Volume
1.39M
Price
3.64
IPO
Mar 22, 2022
Option/Short
Yes / Yes
Trades
Volume
6,509,258
Change
1.11%
Date Action Analyst Rating Change Price Target Change
May-06-26Downgrade BTIG Research Buy → Neutral
Apr-10-25Initiated Mizuho Neutral $15
Dec-02-24Upgrade Morgan Stanley Underweight → Equal-Weight $13 → $20
Nov-27-24Upgrade BTIG Research Neutral → Buy $26
Oct-20-23Initiated Wolfe Research Peer Perform
Jan-06-23Downgrade Morgan Stanley Equal-Weight → Underweight $28
Sep-08-22Initiated BTIG Research Neutral
Aug-01-22Initiated Morgan Stanley Equal-Weight $33
Jun-21-22Initiated BofA Securities Underperform $25
May-08-26 09:00AM
May-05-26 04:53PM
06:30AM
06:30AM
Apr-21-26 05:00PM
06:35AM Loading…
Mar-20-26 06:35AM
Mar-19-26 10:37AM
06:30AM
Feb-11-26 04:10PM
Feb-05-26 05:30PM
02:02PM
06:30AM
06:00AM
Jan-22-26 05:00PM
Dec-18-25 05:00PM
02:01PM Loading…
Nov-25-25 02:01PM
06:30AM
06:00AM
Nov-20-25 07:50AM
Nov-17-25 05:00PM
Nov-14-25 06:30AM
Nov-11-25 05:00PM
Oct-06-25 05:15AM
Sep-15-25 08:06AM
05:37AM
Sep-09-25 04:12AM
Aug-26-25 05:00PM
Aug-25-25 09:30AM
Aug-12-25 09:55AM
Aug-09-25 03:03AM
06:30AM Loading…
Aug-08-25 06:30AM
06:00AM
Jul-24-25 05:00PM
Jul-13-25 12:27AM
Jul-10-25 11:13AM
May-27-25 05:00PM
May-22-25 06:30AM
May-13-25 10:50AM
May-10-25 05:16AM
03:03AM
May-09-25 12:10PM
07:40AM
06:30AM
06:00AM
May-08-25 05:15PM
May-07-25 11:35AM
Apr-28-25 07:30AM
Apr-22-25 03:51AM
Apr-21-25 05:00PM
Apr-01-25 08:05AM
Feb-19-25 03:36PM
Feb-18-25 05:00PM
Feb-07-25 02:09AM
Feb-06-25 07:45AM
06:30AM
06:00AM
Jan-23-25 05:00PM
Dec-19-24 05:00PM
Dec-09-24 08:50AM
Dec-06-24 06:00AM
Nov-27-24 06:40AM
02:02AM
12:26AM
Nov-26-24 01:15PM
07:40AM
06:40AM
06:30AM
06:00AM
Nov-18-24 10:00AM
Nov-12-24 05:31PM
05:00PM
Nov-07-24 06:30AM
Sep-03-24 07:55AM
06:30AM
Aug-22-24 05:00PM
Aug-12-24 09:35AM
09:30AM
Aug-10-24 08:18AM
Aug-09-24 10:52AM
07:40AM
06:30AM
06:00AM
Aug-02-24 10:00AM
Jul-31-24 09:47AM
Jul-29-24 08:05AM
Jul-24-24 04:21AM
Jul-22-24 07:42AM
Jul-18-24 05:00PM
Jun-25-24 07:47AM
Jun-24-24 06:30AM
Jun-20-24 07:30AM
May-21-24 04:30PM
May-13-24 11:52AM
May-10-24 02:12PM
May-09-24 10:54AM
06:30AM
06:00AM
May-01-24 05:00PM
Apr-23-24 05:00PM
Mar-06-24 06:00AM
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Melcher David FDirectorMay 23 '25Buy10.6010,000105,99586,681May 23 04:35 PM